MCID: ESN020
MIFTS: 47

Eosinophilic Granulomatosis with Polyangiitis

Categories: Rare diseases, Neuronal diseases, Cardiovascular diseases, Nephrological diseases, Respiratory diseases, Bone diseases, Immune diseases

Aliases & Classifications for Eosinophilic Granulomatosis with Polyangiitis

MalaCards integrated aliases for Eosinophilic Granulomatosis with Polyangiitis:

Name: Eosinophilic Granulomatosis with Polyangiitis 53 59 37
Churg-Strauss Syndrome 53 59 73
Granulomatous Allergic Angiitis 53 59
Egpa 53 59
Allergic Angiitis and Granulomatosis 53
Allergic Granulomatous and Angiitis 53
Churg-Strauss Vasculitis 53
Allergic Granulomatosis 53
Css 53

Characteristics:

Orphanet epidemiological data:

59
eosinophilic granulomatosis with polyangiitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),<1/1000000 (Sweden),1-9/100000 (France),1-9/100000 (Sweden),<1/1000000 (United Kingdom),1-9/100000 (Norway),<1/1000000 (Spain),1-9/100000 (Australia),1-9/1000000 (Europe),1-9/100000 (Worldwide),<1/1000000 (Norway),1-9/1000000 (Germany),1-9/1000000 (Lithuania),1-9/1000000 (France),1-9/100000 (Germany),1-9/100000 (Japan); Age of onset: Adolescent,Adult,Elderly; Age of death: adolescent,adult,elderly,young Adult;

Classifications:



Summaries for Eosinophilic Granulomatosis with Polyangiitis

NIH Rare Diseases : 53 Eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome) is a condition characterized by asthma, high levels of eosinophils (a type of white blood cell that helps fight infection), and inflammation of small to medium sized blood vessels (vasculitis). The inflamed vessels can affect various organ systems including the lungs, gastrointestinal tract, skin, heart and nervous system. The exact cause of eosinophilic granulomatosis with polyangiitis is unknown, but it is thought to be an autoimmune disorder. Treatment may involve the use of glucocorticoids (steroids) and/or other immunosuppressive therapies. As of December 2017, mepolizumab (Nucala) became the first therapy approved specifically to treat eosinophilic granulomatosis with polyangiitis. When added to traditional steroid or immunosuppressive therapy, mepolizumab has been found to increase remission rate and time in remission for 50% of people with eosinophilic granulomatosis with polyangiitis.

MalaCards based summary : Eosinophilic Granulomatosis with Polyangiitis, also known as churg-strauss syndrome, is related to churg-strauss syndrome and allergic angiitis. An important gene associated with Eosinophilic Granulomatosis with Polyangiitis is IL27 (Interleukin 27). The drugs Methotrexate and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include skin, heart and lung, and related phenotypes are renal insufficiency and proteinuria

Wikipedia : 76 Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg–Strauss syndrome (CSS) or... more...

Related Diseases for Eosinophilic Granulomatosis with Polyangiitis

Diseases related to Eosinophilic Granulomatosis with Polyangiitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Related Disease Score Top Affiliating Genes
1 churg-strauss syndrome 11.6
2 allergic angiitis 11.6
3 anca-associated vasculitis 11.3
4 wegener granulomatosis 11.0
5 vasculitis 10.4
6 neuropathy 10.3
7 asthma 10.3
8 aspergillosis 10.2
9 hepatitis 10.2
10 hypereosinophilic syndrome 10.2
11 allergic bronchopulmonary aspergillosis 10.1
12 mononeuritis multiplex 10.1
13 cholecystitis 10.1
14 peripheral nervous system disease 10.1
15 myocarditis 10.1
16 hepatitis b 10.0
17 thrombosis 10.0
18 cardiac tamponade 10.0
19 polyneuropathy 10.0
20 cerebritis 10.0
21 systemic lupus erythematosus 9.9
22 myositis 9.9
23 temporal arteritis 9.9
24 hemolytic uremic syndrome, atypical 1 9.9
25 stroke, ischemic 9.9
26 hypereosinophilic syndrome, idiopathic 9.9
27 myocardial infarction 9.9
28 polyarteritis nodosa, childhood-onset 9.9
29 acute myocardial infarction 9.9
30 autoimmune hepatitis 9.9
31 dilated cardiomyopathy 9.9
32 granuloma annulare 9.9
33 sinusitis 9.9
34 spinal stenosis 9.9
35 invasive aspergillosis 9.9
36 lymphoma 9.9
37 colitis 9.9
38 angioimmunoblastic t-cell lymphoma 9.9
39 sialadenitis 9.9
40 endocarditis 9.9
41 sarcoma 9.9
42 retinal vasculitis 9.9
43 hemolytic-uremic syndrome 9.9
44 endomyocardial fibrosis 9.9
45 patent foramen ovale 9.9
46 optic nerve disease 9.9
47 intestinal perforation 9.9
48 cryoglobulinemia 9.9
49 myelitis 9.9
50 ischemia 9.9

Graphical network of the top 20 diseases related to Eosinophilic Granulomatosis with Polyangiitis:



Diseases related to Eosinophilic Granulomatosis with Polyangiitis

Symptoms & Phenotypes for Eosinophilic Granulomatosis with Polyangiitis

Human phenotypes related to Eosinophilic Granulomatosis with Polyangiitis:

59 32 (show top 50) (show all 53)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
2 proteinuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0000093
3 sinusitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000246
4 hematuria 59 32 frequent (33%) Frequent (79-30%) HP:0000790
5 hypertension 59 32 frequent (33%) Frequent (79-30%) HP:0000822
6 cutis marmorata 59 32 occasional (7.5%) Occasional (29-5%) HP:0000965
7 purpura 59 32 hallmark (90%) Very frequent (99-80%) HP:0000979
8 skin rash 59 32 frequent (33%) Frequent (79-30%) HP:0000988
9 urticaria 59 32 hallmark (90%) Very frequent (99-80%) HP:0001025
10 hypopigmented skin patches 59 32 frequent (33%) Frequent (79-30%) HP:0001053
11 acrocyanosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001063
12 gait disturbance 59 32 frequent (33%) Frequent (79-30%) HP:0001288
13 arthritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001369
14 subcutaneous nodule 59 32 occasional (7.5%) Occasional (29-5%) HP:0001482
15 congestive heart failure 59 32 hallmark (90%) Very frequent (99-80%) HP:0001635
16 hypertrophic cardiomyopathy 59 32 frequent (33%) Frequent (79-30%) HP:0001639
17 myocardial infarction 59 32 occasional (7.5%) Occasional (29-5%) HP:0001658
18 abnormal pericardium morphology 59 32 frequent (33%) Frequent (79-30%) HP:0001697
19 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
20 eosinophilia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001880
21 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
22 tubulointerstitial nephritis 59 32 frequent (33%) Frequent (79-30%) HP:0001970
23 dysphagia 59 32 frequent (33%) Frequent (79-30%) HP:0002015
24 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
25 gastroesophageal reflux 59 32 occasional (7.5%) Occasional (29-5%) HP:0002020
26 malabsorption 59 32 occasional (7.5%) Occasional (29-5%) HP:0002024
27 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
28 respiratory insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0002093
29 asthma 59 32 hallmark (90%) Very frequent (99-80%) HP:0002099
30 abnormality of the pleura 59 32 frequent (33%) Frequent (79-30%) HP:0002103
31 hemoptysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002105
32 pulmonary infiltrates 59 32 hallmark (90%) Very frequent (99-80%) HP:0002113
33 transient ischemic attack 59 32 occasional (7.5%) Occasional (29-5%) HP:0002326
34 vasculitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002633
35 arthralgia 59 32 frequent (33%) Frequent (79-30%) HP:0002829
36 autoimmunity 59 32 hallmark (90%) Very frequent (99-80%) HP:0002960
37 myalgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003326
38 hemiplegia/hemiparesis 59 32 occasional (7.5%) Occasional (29-5%) HP:0004374
39 venous thrombosis 59 32 frequent (33%) Frequent (79-30%) HP:0004936
40 intestinal obstruction 59 32 occasional (7.5%) Occasional (29-5%) HP:0005214
41 recurrent intrapulmonary hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0006535
42 cranial nerve paralysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0006824
43 central nervous system degeneration 59 32 hallmark (90%) Very frequent (99-80%) HP:0007009
44 peripheral neuropathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0009830
45 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
46 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
47 myocarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012819
48 nasal polyposis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100582
49 endocarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100584
50 myositis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100614

GenomeRNAi Phenotypes related to Eosinophilic Granulomatosis with Polyangiitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Negative genetic interaction between PTEN-/- and PTEN+/+ GR00255-A-3 8.62 IL27 MPO

Drugs & Therapeutics for Eosinophilic Granulomatosis with Polyangiitis

Drugs for Eosinophilic Granulomatosis with Polyangiitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 64)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 2 1959-05-2, 59-05-2 126941
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
3
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-24-8 5755
4
Azathioprine Approved Phase 4,Phase 3,Early Phase 1 446-86-6 2265
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Not Applicable 83-43-2 6741
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
7
rituximab Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 174722-31-7 10201696
8
Mycophenolic acid Approved Phase 4 24280-93-1 446541
9
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
10
leucovorin Approved, Nutraceutical Phase 4,Phase 2 58-05-9 143 6006
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
12 Prednisolone acetate Phase 4,Phase 3,Not Applicable
13 Alkylating Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 glucocorticoids Phase 4,Phase 3,Phase 2,Not Applicable
15 Methylprednisolone acetate Phase 4,Phase 3,Not Applicable
16 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Not Applicable
17 Folic Acid Antagonists Phase 4,Phase 2
18 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
19 Neuroprotective Agents Phase 4,Phase 3,Not Applicable
20 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
21 Dermatologic Agents Phase 4,Phase 2,Not Applicable
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2
23 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
25 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
26 Vitamin B Complex Phase 4,Phase 2
27 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
28 Prednisolone hemisuccinate Phase 4,Phase 3,Not Applicable
29 Prednisolone phosphate Phase 4,Phase 3,Not Applicable
30 Anti-Infective Agents Phase 4,Not Applicable
31 Antiemetics Phase 4,Phase 3,Not Applicable
32 Protective Agents Phase 4,Phase 3,Not Applicable
33 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
35 Antimetabolites Phase 4,Phase 3,Phase 2
36 Autonomic Agents Phase 4,Phase 3,Not Applicable
37 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
38 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Not Applicable
39 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Not Applicable
40 Anti-Bacterial Agents Phase 4
41 Antibiotics, Antitubercular Phase 4
42 Antitubercular Agents Phase 4
43 Folate Nutraceutical Phase 4,Phase 2
44 Vitamin B9 Nutraceutical Phase 4,Phase 2
45 Antibodies Phase 3,Phase 2
46 Immunoglobulins Phase 3,Phase 2
47 Pharmaceutical Solutions Phase 3
48 Rho(D) Immune Globulin Phase 3
49 gamma-Globulins Phase 3
50 Immunoglobulin G Phase 3

Interventional clinical trials:

(show all 43)
# Name Status NCT ID Phase Drugs
1 CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors Unknown status NCT00399399 Phase 4 azathioprine;cyclophosphamide
2 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
3 Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Recruiting NCT03164473 Phase 4 Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
4 A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Completed NCT02020889 Phase 3 Placebo
5 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
6 Rituximab in Eosinophilic Granulomatosis With Polyangiitis Recruiting NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
7 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) Recruiting NCT02836496 Phase 3 Mepolizumab 300 mg;Placebo matching mepolizumab;Active OCS capsules (5 mg prednisolone or prednisone);Placebo matching OCS capsules
8 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
9 Intravenous Immunoglobulin After Relapse in Vasculitis Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
10 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
11 Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Completed NCT00527566 Phase 1, Phase 2
12 Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome Completed NCT00716651 Phase 2 mepolizumab
13 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
14 Steroids and Methotrexate to Treat Systemic Vasculitis Completed NCT00001256 Phase 2 prednisone and methotrexate
15 Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Recruiting NCT02947945 Phase 2 Reslizumab
16 Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Recruiting NCT03010436 Phase 2 Benralizumab
17 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Not yet recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
18 Rituxan in Churg Strauss Syndrome With Renal Involvement Terminated NCT00424749 Phase 2 Rituximab;Prednisone
19 Abatacept in ANCA Associated Vasculitis Terminated NCT00482066 Phase 2 Abatacept (Orencia)
20 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1
21 PRO Development for ANCA Associated Vasculitis Unknown status NCT01729624
22 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 Not Applicable anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
23 RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Completed NCT00307593 Not Applicable Infliximab;Rituximab
24 Educational Needs of Patients With Systemic Vasculitis Completed NCT02190929
25 The ANCA Vasculitis Questionnaire (AAV-PRO©) Completed NCT02507024
26 Vasculitis Illness Perception (VIP) Study Completed NCT02190916
27 Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
28 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
29 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
30 Eosinophilic Granulomatosis With Polyangiitis Cohort Recruiting NCT03036670
31 Determining Disease Activity Biomarkers in Individuals With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Recruiting NCT00315380
32 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Recruiting NCT01066208
33 Pediatric Vasculitis Initiative Recruiting NCT02006134
34 VCRC Tissue Repository Recruiting NCT02967068
35 Vasculitis Pregnancy Registry Recruiting NCT02593565
36 One-Time DNA Study for Vasculitis Recruiting NCT01241305
37 Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Recruiting NCT03004326
38 Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE) Recruiting NCT03373045
39 Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) Active, not recruiting NCT01862068
40 Survey of Patients With Idiopathic Orbital Inflammation Syndrome Active, not recruiting NCT01443000
41 VCRC Patient Contact Registry Patient-Reported Data Validation Study Enrolling by invitation NCT02190942
42 NUCALA® Special Drug Use Investigation (EGPA, Long-term) Not yet recruiting NCT03557060 Nucala
43 Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome Terminated NCT02728271 Early Phase 1

Search NIH Clinical Center for Eosinophilic Granulomatosis with Polyangiitis

Genetic Tests for Eosinophilic Granulomatosis with Polyangiitis

Anatomical Context for Eosinophilic Granulomatosis with Polyangiitis

MalaCards organs/tissues related to Eosinophilic Granulomatosis with Polyangiitis:

41
Skin, Heart, Lung, Neutrophil, Bone, T Cells, Small Intestine

Publications for Eosinophilic Granulomatosis with Polyangiitis

Articles related to Eosinophilic Granulomatosis with Polyangiitis:

(show top 50) (show all 196)
# Title Authors Year
1
Eosinophilic granulomatosis with polyangiitis in children: Data from the French RespiRareAr cohort. ( 29943913 )
2018
2
Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies. ( 29611001 )
2018
3
Multiple Cerebral Infarctions Due to Patent Foramen Ovale in a Patient with Eosinophilic Granulomatosis with Polyangiitis. ( 29373226 )
2018
4
Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis. ( 29908086 )
2018
5
A Case of dilated Cardiomyopathy with Eosinophilic Granulomatosis with Polyangiitis in which Active Myocardial Inflammation was Only Detected by Endomyocardial Biopsy. ( 29709930 )
2018
6
Mepolizumab Treatment of Pediatric Eosinophilic Granulomatosis With Polyangiitis. ( 29466544 )
2018
7
Comparison of findings on thoracic computed tomography with the severity and duration of bronchial asthma in patients with eosinophilic granulomatosis with polyangiitis. ( 29857992 )
2018
8
Eosinophilic granulomatosis with polyangiitis and laryngeal involvement: review of the literature and a cross-sectional prospective experience. ( 29888684 )
2018
9
Overall Disability Sum Score for Clinical Assessment of Neurological Involvement in Eosinophilic Granulomatosis With Polyangiitis. ( 29652700 )
2018
10
A Rare Case of Eosinophilic Granulomatosis with Polyangiitis Associated with Cryoglobulinemia Presenting with a Bullous Skin Eruption of the Lower Limbs. ( 29560002 )
2018
11
Histopathological Findings and Increased D-Dimer Are Predictive Factors of Systemic Thromboses in Eosinophilic Granulomatosis With Polyangiitis. ( 29979194 )
2018
12
Focus on the Involvement of the Nose and Paranasal Sinuses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Nasal Cytology Reveals Infiltration of Eosinophils as a Very Common Feature. ( 29393242 )
2018
13
Polyps, grommets and eosinophilic granulomatosis with polyangiitis. ( 29310745 )
2018
14
Longterm Outcomes of 188 Japanese Patients with Eosinophilic Granulomatosis with Polyangiitis. ( 29907668 )
2018
15
Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review. ( 29766394 )
2018
16
HBsAg-negative and anti-HBc-positive in eosinophilic granulomatosis with polyangiitis: a retrospective pilot study. ( 29754328 )
2018
17
Eosinophilic granulomatosis with polyangiitis: A case report. ( 29428428 )
2018
18
Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. ( 29637936 )
2018
19
Eosinophilic Granulomatosis with Polyangiitis Manifested by Cholecystitis and Mononeuritis Multiplex: A Case Report. ( 29892153 )
2018
20
Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report. ( 29564565 )
2018
21
Angioimmunoblastic T-cell lymphoma mimicking eosinophilic granulomatosis with polyangiitis (Churg-Strauss). ( 29966769 )
2018
22
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors. ( 29936437 )
2018
23
Development of Hypertrophic Pachymeningitis in a Patient With Antineutrophil Cytoplasmic Antibody-Negative Eosinophilic Granulomatosis With Polyangiitis. ( 29485545 )
2018
24
Intracranial vasculitis in eosinophilic granulomatosis with polyangiitis. ( 29901786 )
2018
25
Clinical Characteristics and Treatment Response of Peripheral Neuropathy in the Presence of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Experience at a Single Tertiary Center. ( 28079316 )
2017
26
Lesson of the month 1: Beware the atypical presentation: eosinophilic granulomatosis with polyangiitis presenting as acute coronary syndrome. ( 28365634 )
2017
27
Cardiac involvement as a presenting feature of eosinophilic granulomatosis with polyangiitis in childhood. ( 28339359 )
2017
28
Eosinophilic granulomatosis with polyangiitis complicated by subarachnoid hemorrhage and coronary vasculitis: a case report and review of the literature. ( 29127573 )
2017
29
Koebner Phenomenon in Eosinophilic Granulomatosis with Polyangiitis (Churg-Srauss). ( 28421235 )
2017
30
Five factor score more than 1 is associated with relapse during the first 2 year-follow up in patients with eosinophilic granulomatosis with polyangiitis. ( 28261989 )
2017
31
Cardiac involvement in eosinophilic granulomatosis with polyangiitis. ( 29177893 )
2017
32
Interferon-I+ for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center Retrospective Observational Cohort Study. ( 28412705 )
2017
33
Neurological Complications in Eosinophilic Granulomatosis with Polyangiitis (EGPA): The Roles of History and the Results of Physical Examinations in the Diagnosis of EGPA. ( 28924115 )
2017
34
Eosinophilic granulomatosis with polyangiitis - toward personalized treatment. ( 28950436 )
2017
35
Recurrent Transitory Ischemic Attacks with Subsequent Development of the Ischemic Stroke as Initial Manifestation of Eosinophilic Granulomatosis with Polyangiitis in Depressed Patient. ( 29197212 )
2017
36
Appendiceal Perforation in Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). ( 29293115 )
2017
37
Diaphragmatic paralysis in eosinophilic granulomatosis with polyangiitis. ( 28578879 )
2017
38
Eosinophilic granulomatosis with polyangiitis followed by venous thromboembolism resulting in severe cutaneous ulcers. ( 28556974 )
2017
39
Eosinophilic granulomatosis with polyangiitis - new definition, new treatment? - comment of the article by PuAcchal et al. ( 28950437 )
2017
40
Antiproteinase 3 Positive Eosinophilic Granulomatosis with Polyangiitis Presenting with Heart Failure and Intraventricular Thrombosis. ( 28251013 )
2017
41
Demographic and Clinical Characteristics Associated with Central Nervous System Hemorrhage in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Case Report and Review of the Literature. ( 28864668 )
2017
42
Two cases of atypical hemolytic uremic syndrome (aHUS) and eosinophilic granulomatosis with polyangiitis (EGPA): a possible relationship. ( 28509134 )
2017
43
Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). ( 28094120 )
2017
44
Vasculitis: Mepolizumab for eosinophilic granulomatosis with polyangiitis. ( 28769112 )
2017
45
Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome) Complicated by Perforation of the Small Intestine and Cholecystitis. ( 29269641 )
2017
46
Basophil and M2 macrophage infiltration in lesional skin of eosinophilic granulomatosis with polyangiitis. ( 28943503 )
2017
47
Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis with Polyangiitis, Microscopic Polyangiitis or Polyarteritis Nodosa without Poor Prognosis Factors A Randomized-Controlled Trial. ( 28678392 )
2017
48
Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis. ( 28814426 )
2017
49
The key clues to reach the diagnosis of Loeffler endomyocardial fibrosis associated with eosinophilic granulomatosis with polyangiitis. ( 28072629 )
2017
50
Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). ( 28762062 )
2017

Variations for Eosinophilic Granulomatosis with Polyangiitis

Expression for Eosinophilic Granulomatosis with Polyangiitis

Search GEO for disease gene expression data for Eosinophilic Granulomatosis with Polyangiitis.

Pathways for Eosinophilic Granulomatosis with Polyangiitis

GO Terms for Eosinophilic Granulomatosis with Polyangiitis

Sources for Eosinophilic Granulomatosis with Polyangiitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....